RxDoctor Payments Data

Devon Beneby, APRN

Psychiatric/Mental Health · Bunnell, FLNPI 1932887338

Payments from drug & device makers

$2,666in general payments, 2019–2025

Across 93 payments — averaging $28.67 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.)$717
  • AbbVie$532
  • Johnson & Johnson$316
  • Teva Pharmaceuticals USA, Inc.$302
  • Otsuka America Pharmaceutical, Inc.$216
  • Axsome Therapeutics, Inc.$177
  • plus $406 from 8 others

What the payments were for

  • Food & beverage$2,666100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$2,666 in reported general payments places this provider in the 75th percentile of 3,096 psychiatric/mental health providers in Florida.

See all psychiatric/mental health providers in Florida

Medicare billing

Part B allowed, 2024
$12,520
Medicare patients
75
Services billed
188

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
Invega SustennaPaliperidone Palmitate47$152,089
VraylarCariprazine Hcl52$74,470
Abilify MaintenaAripiprazole21$56,274
Aripiprazole99$13,085
Quetiapine Fumarate184$3,350
Lurasidone Hcl30$3,157
Paliperidone ErPaliperidone14$2,046
Olanzapine100$2,032
Divalproex Sodium ErDivalproex Sodium46$1,817
Divalproex Sodium59$1,186
Hydroxyzine Hcl63$1,166
Haloperidol45$1,086
Benztropine Mesylate106$1,084
Duloxetine Hcl79$1,071
Haloperidol Decanoate19$960

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Johnson & JohnsonInvega Sustenna$316$152,08947 claims
AbbVieVraylar$532$74,47052 claims
Otsuka America Pharmaceutical, Inc.Abilify Maintena$216$56,27421 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 75th percentile of 3,096 psychiatric/mental health providers in Florida.

Other psychiatric/mental health in Bunnell

See the full list for Florida

Where these figures come from

Is this you, or does something look wrong? →